GlobeNewswire by notified

Alvotech Announces Participation at BofA Securities Healthcare Conference 2024

Share

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of management would be participating in the upcoming BofA Securities Healthcare Conference 2024, which will be held on May 14-15, 2024 in Las Vegas, NV.

Members of Alvotech’s management team will be attending the conference and hosting one-on-one meetings with investors.

About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, Senior Director
alvotech.ir@alvotech.com

FOR MORE INFORMATION
Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, X and YouTube.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Metasphere Labs Announces Development of Innovative Carbon Credit Protocol for Grid-Scale Batteries24.5.2024 22:05:00 CEST | Press release

VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is excited to announce an innovative initiative aimed at accelerating the decarbonization of the electricity grid through the development of a pioneering carbon credit protocol for grid-scale batteries. Innovative Carbon Credit Protocol The Company is committed to leveraging advanced technology to address critical environmental challenges. The new carbon credit protocol will enable grid-scale batteries to monetize their environmental attributes by generating carbon credits for the carbon reductions achieved through optimized battery operations. This protocol is designed to incentivize the deployment and operation of grid-scale batteries, ensuring they play a pivotal role in the transition to a clean energy future. Submission to Pure Sky Carbon Credit Registry The Company intends to submit this pr

Nokia Corporation: Repurchase of own shares on 24.05.202424.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 24 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 24.05.2024 Espoo, Finland – On 24 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL362,1533.55CEUX--BATE--AQEU--TQEX--Total362,1533.55 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Udnævnelse af ny CFO24.5.2024 20:05:00 CEST | pressemeddelelse

MEDDELELSE NR. 269 Udnævnelse af ny CFO Bestyrelsen i ChemoMetec har med virkning fra 1. juli 2024 ansat Kim Nicolajsen som ny CFO. Kim Nicolajsen kommer fra en tilsvarende stilling som CFO i den familieejede virksomhed Rohde Nielsen. Han er statsautoriseret revisor og har tidligere arbejdet for KPMG og EY. Bestyrelsen har samtidig indgået aftale med selskabets nuværende CFO Niels Høy Nielsen om, at han fratræder sin stilling samtidig med Kim Nicolajsens tiltræden. Bestyrelsen vil gerne takke Niels Høy Nielsen for hans indsats i ChemoMetec og for det gode samarbejde. Direktionen i ChemoMetec vil herefter bestå af CEO Martin Helbo Behrens og CFO Kim Nicolajsen. Yderligere oplysninger Bestyrelsesformand Niels Thestrup Telefon: (+45) 3370 2000 CEO Martin Helbo Behrens Telefon: (+45) 4813 1020 Om ChemoMetec A/S ChemoMetec udvikler, producerer og markedsfører instrumenter til celletælling og en lang række andre målinger. ChemoMetecs instrumenter markedsføres globalt inden for blandt andet f

Appointment of new CFO24.5.2024 20:05:00 CEST | Press release

ANNOUNCEMENT NO. 269 Appointment of new CFO The board of ChemoMetec has appointed Kim Nicolajsen as new CFO with effect from 1 July 2024. Kim Nicolajsen comes from a similar position as CFO in the family-owned company Rohde Nielsen. He is state-authorized public accountant and has previously worked for KPMG and EY. The board has also entered into an agreement with the company's current CFO Niels Høy Nielsen that he will resign from his position at the same time as Kim Nicolajsen takes over. The board would like to thank Niels Høy Nielsen for his contribution to ChemoMetec and for the good cooperation. CEO Martin Helbo Behrens and CFO Kim Nicolajsen will hereafter form the executive management of ChemoMetec. For further information Chairman of the Board Niels Thestrup Phone: (+45) 3370 2000 CEO Martin Helbo Behrens Phone: (+45) 4813 1020 About ChemoMetec A/S ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s i

Interim Report January – March 202424.5.2024 19:35:00 CEST | Press release

First quarter 2024 (compared to first quarter 2023) Net sales for the quarter amounted to MSEK 13 (13)Gross margin for the quarter decreased to 67% (74%)Operating loss amounted to MSEK -14 (-14)Earnings per share before and after dilution decreased to SEK 0.00 (-0.12) The report for January – March 2024 is available in its entirety on the following address: https://www.anoto.com/investors/reports/ For further information contact: Kevin Adeson, Chairman of the Board of Directors For more information about Anoto, visit www.anoto.com or email ir@anoto.com Anoto Group AB (publ), Reg.No. 556532-3929, Flaggan 1165, 116 74 Stockholm This information constitutes inside information as Anoto Group AB (publ) is obliged to disclose under the EU Market Abuse Regulation 596/2014. The information was provided by the contact person above for publication on 24 May 2024 at 19:30 CEST. About Anoto Group Anoto is a publicly held Swedish technology company known globally for innovation in the area of infor

HiddenA line styled icon from Orion Icon Library.Eye